1. Market Research
  2. > Healthcare
  3. > Medical Facility Market Trends
  4. > CRO Quality Benchmarking – Phase IV Service Providers (8th edition)

CRO Quality Benchmarking – Phase IV Service Providers (8th edition)

  • March 2016
  • -
  • Industry Standard Research
  • -
  • 156 pages

ISR’s “CRO Quality Benchmarking – Phase IV Service Providers” report provides pharmaceutical sponsors and service providers a Consumer Reports-style analysis of CRO quality. Respondents supplied performance ratings based on their own experiences with 44 Phase IV CROs, making this report the most comprehensive assessment of CRO service quality in the industry. Now in its 8th year, this report has become a crucial tool for sponsors looking to select a Phase IV CRO and for service providers seeking an experience-based evaluation of their strengths and weaknesses.

How you can use this report
STUDY SPONSORS
- Make a more informed purchase of Phase IV services by understanding which service providers best fit your company’s needs
- Broaden your Phase IV CRO evaluation list by accessing peer-based service quality ratings across 26 critical attributes
- Pinpoint potential delivery concerns early in a sponsor
- CRO relationship/ evaluation in order to develop proactive strategies to address potential gaps

CLINICAL SERVICE PROVIDERS
- Uncover your own - and competitor - delivery strengths and weaknesses
- Design messaging to tout your company’s strengths
- Compete more effectively by understanding buyers’ selection criteria and outsourcing trends

FOR PHARMA
Make a more informed purchase of Phase IV CRO services by understanding which service providers best fit your company’s needs.
FOR CROS
Uncover your perceived strengths and weaknesses based on customer reviews, and compare your services to those of your competitors.

Table Of Contents

CRO Quality Benchmarking - Phase IV Service Providers (8th edition)
COPYRIGHT AND USAGE
GUIDELINES
INTRODUCTION
METHODOLOGY
RESPONDENT DEMOGRAPHICS AND QUALIFICATIONS
Participant Years of Industry
Experience
Participant Geography
Participant Company Size
NUMBER OF RATINGS PER COMPANY
5 MAJOR SECTIONS
SERVICE PROVIDER SELECTION PROCESS
Primary Section Takeaways
Figure 1 - Preferred Provider Agreements
Figure 2 - Selection Attributes
SERVICE PROVIDER PERCEPTIONS AND INTERACTIONS
Primary Section Takeaways
Figure 3 - Phase IV Leadership, Familiarity, and Use
Figure 4 - Service Provider Preference
Figure 5 - Service Provider Preference Differences by Size
Figure 6 - Cost Experience among Users
Figure 7 - Service Provider Cost Perceptions
Figure 8 - Summary Table
SERVICE PROVIDER
PERFORMANCE AND LOYALTY
Primary Section Takeaways
Budget Factors
Delivery Factors
Organization Factors
Staff Characteristics
Timelines Management
Figure 9 - Budget Factors
Figure 10 - Delivery Factors
Figure 11 - Organization Factors
Figure 12 - Staff Characteristics
Figure 13 - Timelines Management
Figure 14 - Customer Loyalty: 2015
Figure 15 - Customer Loyalty: 3 Year Rolling Average
COMPANY SERVICE QUALITY
PROFILES
Covance
ICON
INC Research
inVentiv Health Clinical
PAREXEL
PPD
PRA
Quintiles
STUDY DATA
Phase IV Leaders, Unprompted Other Responses
Phase IV Leaders, Prompted
Service Provider Familiarity
Service Provider Usage
Service Provider Preference
Service Provider Differentiation
Selection Drivers: Selecting among Preferred Providers
Preferred Provider Attributes Gaining Importance
Selection Drivers Not Using
Preferred Providers Selection Drivers: No Preferred Providers
Service Provider Attributes Gaining Importance: No Preferred Providers
Service Provider Cost Perceptions
Use of Preferred Providers
Number of Preferred Providers
Service Provider Drill-downs
Accelovance
Accenture
Bioclinica
Bioskin
CEBIS International
Chiltern
Clinipace
Clinlogix
Cognizant
Covance
DaVita Clinical Research
DCRI - Duke
Eurofins
Eurotrials
HungaroTrial
ICON
Inamed
INC Research
inVentiv Health Clinical
KCR
Lambda
Mapi
Medpace
Medsource
NAMSA
Novotech
Novum
PAREXEL
Pharm-Olam International
PPD
PRA
ProTrials
QPS
Quintiles
Radiant
Rho
SanaClis
SGS Life Sciences
SynteractHCR
Tata
Theorem
TKL Research
UBC
Worldwide Clinical Trials
Performance Across Service
Providers
DEMOGRAPHICS
Company Type
Headquarters Location
Office Location
Job Title
Decision-making
Responsibility
Outsourcing Involvement by
Phase
Involvement in Clinical
Development
Therapeutic Areas of
Responsibility
Years of Industry Experience
Age
ABOUT INDUSTRY STANDARD RESEARCH

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...

2016 Competing in the Global Cancer Diagnostics Market

2016 Competing in the Global Cancer Diagnostics Market

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

This new VPGMarketResearch.com comprehensive seven-country study identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends ...

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.